ClinicalTrials.gg
TerminatedNCT04274933Updated Oct 29, 2020

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

A Phase 1 interventional study of Venetoclax and Capecitabine in Breast Cancer and Cancer, sponsored by AbbVie. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-29.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Why this study was terminated
Company Decision

From the registry’s dates

  • Primary completion was Oct 2020, 6 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
214th of 227
4 · median 54
Started
2020
with 7 others
Phase 1
28 of 233
none open now
Registered
185th of 233
by date

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 214th largest by enrollment of the 227 interventional ones that give a count, is one of 8 that started in 2020, is one of 28 in phase 1, and was the 185th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment that included a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.

Venetoclax is an investigational drug being developed for the treatment of breast cancer. This study is open-label meaning both the participants and study doctors will know what treatment is being given. The study includes two phases: dose escalation and dose expansion. In dose escalation, participants will receive various doses of venetoclax in combination with capecitabine. In dose expansion, participants will receive the recommended dose of venetoclax determined during dose escalation in combination with capecitabine. Adult participants with locally advanced or MBC that is not amenable to curative therapy will be enrolled. Around 42 participants will be enrolled at approximately 20 sites worldwide.

Venetoclax and capecitabine will be administered on a 21-day cycle. During dose escalation, participants will take various doses of venetoclax as a tablet by mouth once a day and capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks. During dose expansion, participants will take venetoclax at the dose identified during dose escalation as a tablet by mouth once a day and capecitabine as a tablet by mouth twice per day on days 1 - 14 of each cycle for approximately 30 weeks.

There may be a higher burden for participants in this trial compared to standard of care. Participants will attend weekly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and evaluating for side effects.

03

Conditions studied

  • Breast Cancer
  • Cancer

Keywords

  • Breast Cancer
  • Metastatic
  • Locally Advanced
  • Venetoclax
  • Capecitabine
  • Hormone Receptor Positive
  • HER2 Negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of advanced or breast cancer that is hormone receptor positive (HR+) and negative (HER2-).
  • (ECOG) performance score of 0-1.
  • Willing to provide tissue sample prior to start of study treatment, and in participants with , at Day 1 of Cycle 3.

    • Escalation cohort: Able to provide a tissue sample obtained at any time in disease history prior to start of study treatment.
    • Expansion cohort: Able to provide a fresh tissue sample from either primary tumor or metastatic site; if fresh sample collection is deemed unsafe by the investigator, then an archival tissue block is acceptable if obtained at time of most recent progression and within 16 weeks of study treatment.
  • Experienced disease progression during or after CDK4/6 inhibitor therapy administered in combination with endocrine therapy for a minimum of 8 weeks prior to progression.

Exclusion criteria

Exclusion Criteria:

  • History of receiving systemic cytotoxic chemotherapy in the locally advanced or setting.
  • Received anti-cancer therapy within the previous 21 days prior to the start of study drugs.
  • No known uncontrolled metastases to the central nervous system (CNS). Participants with are eligible provided they have shown positive clinical and radiographic stable disease for at least 4 weeks after definitive therapy and have not used for at least 2 weeks prior to first dose of study drugs.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Dose Escalation: Venetoclax and Capecitabine

    Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.

    Drug: Venetoclax · Drug: Capecitabine

  • Experimental
    Dose Expansion: Venetoclax and Capecitabine

    Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.

    Drug: Venetoclax · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose Limiting Toxicities (DLTs)

    Adverse events that are considered by the investigator to have a reasonable possibility of relationship to the administration of venetoclax in combination with capecitabine will be considered a DLT.

    Time frame: Up to 21 days after first dose of study drug

  2. Maximum observed plasma concentration (Cmax) of venetoclax

    Maximum observed plasma concentration (Cmax) of venetoclax

    Time frame: Up to 9 days after first dose of study drug

  3. Maximum observed plasma concentration (Cmax) of capecitabine

    Maximum observed plasma concentration (Cmax) of capecitabine.

    Time frame: Up to 9 days after first dose of study drug

  4. Maximum observed plasma concentration (Cmax) of 5-fluorouracil

    Maximum observed plasma concentration (Cmax) of 5-fluorouracil.

    Time frame: Up to 9 days after first dose of study drug

  5. Time to Cmax (peak time, Tmax) of venetoclax

    Time to Cmax (peak time, Tmax) of venetoclax.

    Time frame: Up to 9 days after first dose of study drug

  6. Time to Cmax (peak time, Tmax) of 5-fluorouracil

    Time to Cmax (peak time, Tmax) of 5-fluorouracil.

    Time frame: Up to 9 days after first dose of study drug

  7. Time to Cmax (peak time, Tmax) of capecitabine

    Time to Cmax (peak time, Tmax) of capecitabine.

    Time frame: Up to 9 days after first dose of study drug

  8. Area under the plasma concentration versus time curve (AUC) for venetoclax up to 24 hours post-dose (AUC0-24)

    Area under the plasma concentration versus time curve for venetoclax up to 24 hours post-dose.

    Time frame: Up to 24 hours

  9. Area under the plasma concentration versus time curve (AUC) for capecitabine/5-fluorouracil up to 12 hours post-dose (AUC0-12)

    Area under the plasma concentration versus time curve for capecitabine/5-fluorouracil up to 12 hours post-dose.

    Time frame: Up to 12 hours

07

Study locations

18 sites
  • Joliet Oncology-Hematology Associates, LTD /ID# 215051
    Joliet, Illinois 60435, United States
  • Massachusetts General Hospital /ID# 214833
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute /ID# 214832
    Boston, Massachusetts 02215, United States
  • Masonic Cancer Center /ID# 216101
    Minneapolis, Minnesota 55455, United States
  • Memorial Sloan Kettering Cancer Center /ID# 214886
    New York, New York 10065-6007, United States
  • University of Pennsylvania /ID# 216357
    Philadelphia, Pennsylvania 19104-5502, United States
  • Greenville Health System Cance /ID# 216059
    Greenville, South Carolina 29605, United States
  • Vanderbilt University Med Ctr /ID# 213852
    Nashville, Tennessee 37232-6307, United States
  • MD Anderson Cancer Center /ID# 214867
    Houston, Texas 77030, United States
  • Utah Cancer Specialists /ID# 215375
    Salt Lake City, Utah 84106, United States
  • Swedish Cancer Institute /ID# 216120
    Seattle, Washington 98104, United States
  • Universitaetsklinik Heidelberg /ID# 214679
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • Universitaetsklinikum Ulm /ID# 214678
    Ulm, Thueringen 89081, Germany
  • Charite Universitaetsmedizin Berlin /ID# 215287
    Berlin, 10117, Germany
  • Universitatsklinikum Tubingen /ID# 217021
    Tuebingen, 72076, Germany
  • Aichi Cancer Center Hospital /ID# 224527
    Nagoya-shi, Aichi 464-8681, Japan
  • Pan American Center for Oncology Trials, LLC /ID# 216862
    Rio Piedras, 00935, Puerto Rico
  • GCM Medical Group PSC - Hato Rey /ID# 216904
    San Juan, 00917-3104, Puerto Rico
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Oct 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2020
First posted
Feb 18, 2020
StartActual
May 21, 2020
Primary completionActual
Oct 8, 2020
CompletionActual
Oct 8, 2020
Last update
Oct 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04274933
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
May 21, 2020
Primary completion
Oct 8, 2020
Completion
Oct 8, 2020
Last update
Oct 29, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Capecitabine

Start the discussion